A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

NCT01814839 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

TTR-mediated Amyloidosis

Interventions

DRUG: ALN-TTRSC (revusiran)
DRUG: Sterile Normal Saline (0.9% NaCl)

Sponsor

Alnylam Pharmaceuticals